Please reserve for your seat at the below eventbrite link for free.
Hypoxia is associated with resistance to radiation and chemotherapy. As tumors grow, they can sense the oxygen tension and reprogram critical pathways necessary for cancer cell survival and therapy resistance. One example is hypoxia-inducible factor alpha (HIF-α) upregulation and activation of HIF signaling downstream pathways. Dr. Zhang’s lab is mainly interested in studying the oxygen-sensing path and how they contribute to the development of tumors and therapeutic resistance. Dr. Zhang’s lab implements novel genomic and proteomic approaches to identify important new therapeutic targets in oxygen-sensing signaling in breast and kidney cancers. During this talk, Dr. Zhang will present on identifying BBOX1 as a new therapeutic target in breast cancer. In addition, Dr. Zhang will present on identifying a few new therapeutic targets in kidney cancer, including ZHX2, SFMBT1, and TBK1.
Medicilon boasts nearly 300 tumor evaluation models. At the same time, we are empowering innovative therapies to comprehensively evaluate and study immuno-oncology. We have completed model establishment and efficacy evaluation of immuno-therapies such as CAR-T, TCR-T, CAR-NK, oncolytic virus, antibody (monoclonal antibody, double antibody, polyclonal antibody, etc.), siRNA, AAV.
Target Identification and Validation in Drug Discovery
Medicilon’s Metabolite Identification Services
Novel Two-Pronged Method Targets Cancer Cells’ Telomerase and Chromosomes
Prostate Cancer Inhibited by Compound against “Undruggable” Target
Relevant
news
marketing@medicilon.com
